Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia

A Pilot Study

Iwamoto, Takuya PhD*; Monma, Fumihiko MD, PhD; Ohishi, Kohshi MD, PhD; Umino, Akira MD, PhD§; Suzuki, Kei MD, PhD; Oka, Koji MD; Kawakami, Keiki MD, PhD**; Sekine, Takao MD††; Okuda, Masahiro PhD*; Katayama, Naoyuki MD, PhD

doi: 10.1097/FTD.0000000000000639
Original Article

Background: Tyrosine kinase inhibitors markedly improve the survival for patients with chronic myeloid leukemia (CML). However, a decrease in adherence leads to undesired therapeutic outcomes. In this study, the relationships among adherence, pharmacokinetics, response, and adverse effects for dasatinib treatment were prospectively investigated.

Methods: This study was a prospective cohort study of patients with newly diagnosed CML at 4 general hospitals and 1 university hospital. Patients started to receive dasatinib 100 mg once daily. A Medication Event Monitoring System was used to assess medication adherence and the medication possession ratio during the 12 months. Plasma concentrations of dasatinib were measured using liquid chromatograph-tandem mass spectrometry (LC-MS/MS), and therapy responses were assessed at 3, 6, and 12 months after treatment.

Results: Ten patients were included. An extremely high medication adherence for dasatinib was observed; the median medication possession ratio was 99.4%. All 9 CML patients with breakpoints in the major BCR-ABL achieved major molecular response (MMR; major BCR-ABL transcript level below 0.1% on the International Scale) within 12 months, and 5 achieved MMR within 6 months. The receiver operating characteristic curve analysis revealed that the cutoff value for the dasatinib area under the concentration–time curve was 336.1 ng × h/mL (accuracy 88.9%, sensitivity 80.0%, specificity 100%, and receiver operating characteristic curve–area under the concentration–time curve 0.800) for achieving MMR within 6 months. Two patients had interrupted dasatinib treatment because of pleural effusion and diarrhea with intestinal edema, respectively. These edematous adverse events developed after plasma dasatinib Cmin surpassed 3.0 ng/mL.

Conclusions: A Medication Event Monitoring System was applied for the direct evaluation of oral dasatinib adherence for the first time, and the clinical effect of dasatinib was investigated under the strict monitoring of patient adherence. Although this study had a small sample size, the plasma concentration monitoring of dasatinib is considered to be useful to predict an earlier molecular response with fewer edematous adverse events.

*Department of Pharmacy, Mie University Hospital;

Department of Hematology and Oncology, Mie University Graduate School of Medicine;

Department of Transfusion Medicine and Cell Therapy, Mie University Hospital;

§Department of Hematology, Yokkaichi Municipal Hospital;

Department of Emergency and Critical Care Center, Mie University Hospital;

Department of Hematology, Suzuka Kaisei Hospital;

**Department of Hematology, JA Mie Suzuka General Hospital; and

††Department of Internal Medicine, Matsusaka Chuo General Hospital, Mie, Japan.

Correspondence: Takuya Iwamoto, PhD, Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie 514-8507, Japan (e-mail:

T. Iwamoto reports grants from Eisai Co, Ltd, Otsuka Pharmaceutical Co, Ltd, Ono Pharmaceutical Co, Ltd, and Technomics, Inc, outside the submitted work. K. Ohishi reports grants from Astellas Pharma Inc, Eisai Co, Ltd, Kyowa Hakko Kirin Co, Ltd, Shionogi & Co, Ltd, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited, outside the submitted work. N. Katayama reports grants from Chugai Pharmaceutical Co, Ltd, Astellas Pharma Inc, Eisai Co, Ltd, Kyowa Hakko Kirin Co, Ltd, Shionogi & Co, Ltd, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited, outside the submitted work. M. Okuda reports grants from Mochida Pharmaceutical Co, Ltd, Torii Pharmaceutical Co, Ltd, MSD Co, Ltd, Eisai Co, Ltd, Otsuka Pharmaceutical Co, Ltd, Otsuka Pharmaceutical Factory, Inc, Ono Pharmaceutical Co, Ltd, AYUMI Pharmaceutical Corporation, Sanofi K.K., Daiichi Sankyo Company Limited, Chugai Pharmaceutical Co, Ltd, Novartis Pharma K.K., Pfizer Japan Inc, EA Pharma Co, Ltd, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Ohara Pharmaceutical Co, Ltd, Teva Pharmaceutical Industries Ltd, Eli Lilly Japan K.K., and Nippon Kayaku Co, Ltd, outside the submitted work.

The authors declare no conflict of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Received December 13, 2018

Accepted February 05, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.